阿司匹林
传统PCI
医学
心脏病学
内科学
急性冠脉综合征
心肌梗塞
作者
Patrícia O. Guimarães,Marcelo Franken,Caio A.M. Tavares,Murillo de Oliveira Antunes,Fábio Serra Silveira,Pedro Beraldo de Andrade,Ricardo Reinaldo Bergo,Rodrigo M Joaquim,João Eduardo Tinoco de Paula,Bruno Ramos Nascimento,Fábio Grunspun Pitta,José Alcides Almeida de Arruda,Renato Giestas Serpa,Louis Nakayama Ohe,Fernanda Mangione,Remo H.M. Furtado,Esmeralci Ferreira,Fernanda B.A. Sampaio,C NASCIMENTO,Luiz O.O. Genelhu
标识
DOI:10.1056/nejmoa2507980
摘要
Among patients who had undergone successful PCI for acute coronary syndromes, potent P2Y12 inhibitor monotherapy was not found to be noninferior to dual antiplatelet therapy with respect to a composite of death or ischemic events at 12 months. (Funded by the Brazilian Ministry of Health; NEO-MINDSET ClinicalTrials.gov number, NCT04360720.).
科研通智能强力驱动
Strongly Powered by AbleSci AI